📊 TECX Key Takeaways
Is Tectonic Therapeutic, Inc. (TECX) a Good Investment?
Tectonic Therapeutic is a pre-revenue biotech company with exceptional financial runway ($253.8M cash, 4+ years at current burn rate) and a pristine balance sheet (0.06x debt-to-equity). However, absent demonstration of clinical or commercial progress, the company remains entirely dependent on R&D success with no proven path to profitability.
Why Buy Tectonic Therapeutic, Inc. Stock? TECX Key Strengths
- Fortress balance sheet with $253.8M cash against only $9.7M total liabilities
- Minimal leverage (0.06x debt-to-equity) provides financial flexibility and zero near-term solvency risk
- Adequate cash runway of 4+ years at current -$60.1M annual operating burn rate, supporting extended development timelines
TECX Stock Risks: Tectonic Therapeutic, Inc. Investment Risks
- Pre-revenue stage with zero commercialized products; company is entirely dependent on R&D pipeline outcomes
- Persistent cash burn of -$60.1M annually with negative ROE (-29.5%) and ROA (-28.4%) indicating no path to profitability without pipeline success
- Binary biotech risk: success contingent on regulatory approvals, clinical trial results, and market adoption; failure would result in total shareholder loss once cash depleted
Key Metrics to Watch
- Operating cash burn rate trend and time-to-depletion calculation
- Clinical trial enrollment, progression, and regulatory milestone achievements
- Revenue inflection and first product commercialization date
Tectonic Therapeutic, Inc. (TECX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 26.63x current ratio provides a solid financial cushion.
TECX Profit Margin, ROE & Profitability Analysis
TECX vs Healthcare Sector: How Tectonic Therapeutic, Inc. Compares
How Tectonic Therapeutic, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tectonic Therapeutic, Inc. Stock Overvalued? TECX Valuation Analysis 2026
Based on fundamental analysis, Tectonic Therapeutic, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tectonic Therapeutic, Inc. Balance Sheet: TECX Debt, Cash & Liquidity
TECX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tectonic Therapeutic, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-6.83 indicates the company is currently unprofitable.
TECX Revenue Growth, EPS Growth & YoY Performance
Tectonic Therapeutic, Inc. Dividends, Buybacks & Capital Allocation
TECX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tectonic Therapeutic, Inc. (CIK: 0001681087)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_080442.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_080427.xml | View → |
| Mar 9, 2026 | 4 | xslF345X05/form4-03092026_100315.xml | View → |
| Mar 9, 2026 | 4 | xslF345X05/form4-03092026_100314.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/form4-03052026_100320.xml | View → |
❓ Frequently Asked Questions about TECX
What is the AI rating for TECX?
Tectonic Therapeutic, Inc. (TECX) has an AI rating of HOLD with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TECX's key strengths?
Claude: Fortress balance sheet with $253.8M cash against only $9.7M total liabilities. Minimal leverage (0.06x debt-to-equity) provides financial flexibility and zero near-term solvency risk.
What are the risks of investing in TECX?
Claude: Pre-revenue stage with zero commercialized products; company is entirely dependent on R&D pipeline outcomes. Persistent cash burn of -$60.1M annually with negative ROE (-29.5%) and ROA (-28.4%) indicating no path to profitability without pipeline success.
What is TECX's revenue and growth?
Tectonic Therapeutic, Inc. reported revenue of N/A.
Does TECX pay dividends?
Tectonic Therapeutic, Inc. does not currently pay dividends.
Where can I find TECX SEC filings?
Official SEC filings for Tectonic Therapeutic, Inc. (CIK: 0001681087) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TECX's EPS?
Tectonic Therapeutic, Inc. has a diluted EPS of $-4.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TECX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tectonic Therapeutic, Inc. has a HOLD rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TECX stock overvalued or undervalued?
Valuation metrics for TECX: ROE of -29.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TECX stock in 2026?
Our dual AI analysis gives Tectonic Therapeutic, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TECX's free cash flow?
Tectonic Therapeutic, Inc.'s operating cash flow is $-60.1M, with capital expenditures of $208.0K.
How does TECX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -29.5% (avg: 15%), current ratio 26.63 (avg: 2).